CheckMate 649: Additional Analysis From the Phase III Trial of First-line Nivolumab + CT vs CT for Advanced Gastroesophageal Cancers

June 4-8, 2021; Online at https://conferences.asco.org/am
In previously untreated patients with advanced gastroesophageal cancers, nivolumab plus chemotherapy significantly prolonged OS and PFS vs chemotherapy alone.
Format: Microsoft PowerPoint (.ppt)
File Size: 462 KB
Released: June 10, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Merck Sharp & Dohme Corp.

Related Content

In this slideset from Clinical Care Options (CCO), experts discuss their thoughts on dosing of regorafenib and TAS-102 for colorectal cancer (CRC).

Kanwal Raghav, MD person default Rachel Riechelmann, MD, PhD Released: October 21, 2021

Short slideset on key trials and approvals for first-generation TRK inhibitors in NTRK fusion+ solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: October 15, 2021

Short expert slideset on when and how to test for NTRK fusions in various solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: October 8, 2021

Expert commentary on the use of PARP inhibitors in the treatment of pancreatic cancer, from Clinical Care Options (CCO)

Dirk Arnold, MD, PhD Released: October 5, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue